



8-PHENYL-ISOQUINOLINES AND PHARMACEUTICAL COMPOSITION THEREOF USED IN THE TREATMENT OF IRRITABLE BOWEL SYNDROME

PI : Prof. Ling-Wei Hsin
School of Pharmacy, National Taiwan U.

Experience:

<http://rx.mc.ntu.edu.tw/myDOP/SCENE/FACULTY/facultyview.php?malangue=&rub=faculty//1//c4ca4238a0b923820dcc509a6f75849b1350911faEySMBUY8B.A>

Market Needs:

Irritable bowel syndrome (IBS) represents a substantial clinical problem that accounts for 10-40% of gastroenterology outpatients in Western and Asian countries.

Our Technology:

The present invention relates to a series of 8-phenylisoquinoline derivatives used in the treatment of IBS.

Strength:

Currently, there is no effective treatment for IBS in clinic. Several marketed drugs were withdraw due to severe side effects and remarketed only under limited circumstances. In addition, there is no drugs in clinic targeting this novel GPCR.

Competing Products:

Antispasmodics, antimobility agents, antibiotics, opioids: all are not effective enough for clinic uses.

Intellectual Properties:

(1) The provisional application for the new compounds, process of synthesis and utilities has been filed. Application Number: 62466370. Filing Date: 03-MAR-2017.

(2) Our team possesses rich experiences in IBS research and drug discovery and development.

Contact (do not need to fill out):

Center for Industry-Academia Cooperation, NTU
Tel: 02-3366-9945, E-mail: ntuciac@ntu.edu.tw